# A Study of BGB324 (Bemcentinib) in Combination With Erlotinib in Patients With Non-Small Cell Lung Cancer

> **NCT02424617** · PHASE1,PHASE2 · COMPLETED · sponsor: **BerGenBio ASA** · enrollment: 40 (actual)

## Conditions studied

- Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** Erlotinib
- **DRUG:** Bemcentinib
- **DRUG:** Bemcentinib
- **DRUG:** Bemcentinib

## Key facts

- **NCT ID:** NCT02424617
- **Lead sponsor:** BerGenBio ASA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-04-19
- **Primary completion:** 2021-08-25
- **Final completion:** 2021-08-25
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2025-02-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02424617

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02424617, "A Study of BGB324 (Bemcentinib) in Combination With Erlotinib in Patients With Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02424617. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*